summary and assessment of research involving renal prostaglandins. Arachidonic acid released from phospholipids is converted by prostaglandin cycle-oxygenase in the kidney to PGE2, PGF,, PGD2, and, possibly, to PGI, and thromboxane AZ. Production of PGE, and PGFz, is predominately but not exclusively in the medulla, whereas degradative enzymes are present in both cortex and medulla. Prostaglandins enter the tubular lumen by facilitated transport and are partially reabsorbed from the urine in the distal nephron. Urine prostaglandins probably reflect renal synthesis. PGEz and endoperoxides stimulate and PGF& and indomethacin inhibit renal renin synthesis. In response to &hernia, vasoconstriction, or angiotensin II the kidney increases prostaglandin synthesis to modulate renal vascular resistance. In conscious animals or man no role has been established for prostaglandins in the maintenance of basal renal blood flow or renal sodium excretion. PGE influences renal water excretion by inhibiting the action vasopressin. Despite conflicting data there is evidence that renal prostaglandins are involved either primarily or secondarily in many types of hypertension. Inhibitors of prostaglandin cyclooxygenase have been used with success in &utter's syndrome. Conflicting results in many areas of investigation may be resolved by the use of more accurate and reliable assays, careful handling of samples, and the use of urine to further investigate renal prostaglandin synthesis.
prostaglandin hormone synthesis; renin-angiotensin; hypertension; antidiuretic OUR 
PURPOSE IN THIS EDITORIAL REVIEW
is to provide a summary and assessment of the research dealing with all aspects of renal prostaglandins.
We attempt to integrate the biochemical and the physiological lines of investigation.
#en it is important we discuss conflicting viewpoints but, overall, citations are selective. Other reviews have recently covered these topics, albeit with different points of emphasis (4, 42, 120, 135, 1AA 147, 220, 240) . Abbreviations PGE2, PGF,,, etc, prostaglandin ES, prostaglandin Fz,, etc. TXA2, TXB%, thromboxane AZ and B2 RBF, renal blood flow BP, blood pressure RIA, radioimmunoassay GC-MS, gas chromatography-mass spectroscopy SHR, spontaneously hypertensive rat
Biochemistry -Synthesis
Prostaglandins and the endoperoxides are synthesized from arachidonic acid by a group of enzymes collectively called prostaglandin synthetase. This group of enzymes includes cycle-oxygenases, peroxidases, isomerases, and reductases (133, 192) . Figure 1 summarizes the sequences of prostaglandin and thromboxane synthesis. The renal medulla and papilla, in all species studied, are a rich source of prostaglandin synthetase (8, 28, 42, 52, 115). However, contrary to earlier negative reports (8), several groups have confirmed that renal cortex can also synthesize small amounts of PGE, and PGF, (52, 115, 117, 180) .
We have found the ratio of activities of the synthetase between papilla, medulla, and cortex in rat and rabbit to be 1OO:lO:l (53) . The prostaglandin synthetase enzymes are microsomal, primarily in the endoplasmic reticulum (8, 30) .
In the kidney the major prostaglandins seem to be PGEz, PGF,,, and PGD2. Although PGE, and PGF,, have been recognized for over a decade as major renal prostaglandins, only recently has PGD, been demonstrated in vitro with radiochemical assays of prostaglandin synthetase (28, 52, 211, 212) and gas chromatography-mass spectroscopy analyses of incubation mediums of renal papillae (168) . There is no evidence that PGA, is a normal enzymatic end product in the kidney (28,42,212). PGA, was not found in amounts exceeding FIG. 1. Biochemical synthetic pathways for prostaglandins and thromboxanes. All depicted conversions are thought to occur in kidney (see text for details).
-. . d -ffic ch4 OH 6-keto-FGF,a EE2 -bz 10% of the PGE, or PGF,, concentration in rabbit medulla or cortex analyzed by GC-MS (117) .
Recently Samuelsson and co-workers (191) described thromboxane AZ, a short-lived compound which has vasoconstrictor and platelet aggregating effects and which is formed fiorn PGG, and PGH, (the endoperoxides). Thromboxane synthetase is present in platelets, lung, spleen, and probably in kidney. Several investigators have reported that thromboxane Bt, the stable metabolite of thromboxane A*, was formed by rat renal homogenates (175) and rabbit and guinea pig renal microsomes (208) and was present in the renal venous effluent of the ex vivo perf&ed rabbit kidney &r 3 days of ureteral obstruction in vivo (152) . It is conceivable that thromboxanes formed by platelets circulating in the kidney may also affect renal physiological processes, especially renal blood flow.
Moncada and co-workers (151) have recently isolated another prostaglandin, originally called prostacyclin but presently named PGIz, which is formed from the endoperoxides by a microsomal enzyme present in ar& rial vasculature. PGI, is vasodilatory and retards platelet aggregation (88) . The stable metabolite of PGI, is 6-keto=PGF,,.
Synthesis of PGI, by the kidney seems likely since incubations of arachidonic acid with rat renal homogenates (175) , rabbit and guinea pig renal microsomes (208) , and human and rat renal cortical microsomes (233) yield detectable amounts of 6-keto-PGF1, measured by GC-MS or thin-layer chromatography. It is not known whether the intrarenal vasculature accounts for a portion of this synthesis in the kidney. There is no information about the physiologic or pathophysiologic roles of TXA, or PG&, but they may be involved in alterations of renal blood flow and disorders of platelet aggregation within glomeruli. synthesis by reducing the amount of arachidonic acid released from phospholipid stores. These steroids have no effect on the prostaglandin synthetase (98), whereas the nonsteroidal anti-inflammatory agents inhibit prostaglandin synthetase. The inhibitory constants for these pharmacologic agents differ between renal, seminal vesicular, and other synthetases. Based on these and other data, Flower and Vane (68) have concluded that the prostaglandin synthetases corn sep arate tissues display different biochemical and pharmacologic profiles.
Biochemistry -Degradation
The metabolism of PGE, and PGF,, is accomplished in the kidney by another group of enzymes. These enzymes dehydrogenate the 15.hydroxyl group (150hydrox-ydehydrogenase), reduce the 13-14 double bond (A-13-reductase), reduce the 9 keto to convert PGE, to PGF,, (9ketoreductase), and oxidize the 9 hydroxyl @hydrox-ydehydrogenase).
Figure 2 depicts these pathways. The 15hydroxydehydrogenase has been the most extensively studied of the four known degradative enzymes (91,137). There are two types of l&hydroxydehy-drogenase: type I which is NAD+dependent and type II 125, 205) . This is a cytoplasmic enzyme which requires which is NADP+-dependent (125) . These are cytosolic NADP as cofactor (124) . PGE&ketoreductase has also, enzymes (125) . In the kidney the type I 15.hydroxydehybeen isolated from lung, brain, heart, spleen, liver, and drogenase is 10 times more concentrated in the cortex blood cells (124) . Whereas swine kidney has similar than the medulla (115, 125) . However, the reverse dis-concentrations of PGE*-9-ketoreductase in renal cortex tribution is found for the type II X-hydroxydehydrogenand medulla (125) , rabbit kidney shows a 10 ti 1 (cortex ase, with twice as much activity in medulla compared to to medulla) gradient of enzymatic activity (206) . K&J cortex and with 12 times more type II than I in medulla and man have not been sitilarly &udied. The enqme (125) . There are species differences for these <enzymes apparently exists in multiple molecular forms in differ-(ill), but it is wrong to conclude that the renal cortex is ent tissues and different species (i.e., different Km, pH the sole degradative site and the renal medulla is the profiles, molecular weights, md isoelectric points) (92, sole synthetic site for PGE, and PGFza. 205 ). McGifY and co-workers (146) have speculated that The specific activity of the 15-hydroxydehydrogenase stimulation and inhibition of renal PGE,-9-ketoreducincreases 59 times in the rat kidney &om birth to 19 tase in vivo may provide important control of the days of age; the A-13.reductase increases 20 times over amount of PGE, converted to the less active form, the same period (173). Pace-Asciak (173) has speculated PGF,,. They have demonstrated that bradykinin dour that increased catabolism of the prostaglandins may bled the conversion of PGE, to PCTF,, using PGE,-9-play a role in nephrogenesis. The renal lfi-hydroxydehyketoreductase obtained from bovine mesenteric veins drogenase has a short half-we, and enzymatic activity (216, 237 Fig. 2 , The PGF, A-13.reductase increases 20 times between birth and 19 days in the rat kidney, parallel to changes of the 16-hydroxydehydro$enase (173). The physiological importance of these changes in the kidney is unknown. Pace-As&& also reported that PGF&&hydroxydehydrogenase was present in adult rat kidney (172) . This enzyme converts 13, 14dihy&~15-keto-PGFz~ to the same metabolite of PGE2. If substantiated in other species this finding suggests caution in evaluating the claim that measurement of urinary metabolites of PGF,, by RIA may provide the best assessment of PGF,, turnover (83, 84) .
Sites of Synthesis and Tubular Transport
The specific cellular sites of synthesis of the pro&a-glandins include the renal medullary interstitial cells (56, 156, 219, 243 ) and the collecting duct (105, 200), although it is likely that other portions of the tubule as well as the glomerulus and arterioles may also synthesize prostaglandins.
The growth of renal medullary interstitial cells in culture has confirmed their extensive capability to synthesize PGEz (56, 156, 243) and has also facilitated in vitro studies of compounds such as angiotensin II, bradykinin, and vasopressin which are potent in vivo and in vitro stimuli of prostaglandin synthesis (243). The granularity of these cells in vivo apparently increases when prostaglandin synthesis is reduced, and the granules are lipid precursors of the prostaglandins (8, 40, 41 (71) . These stop-flow data are difficult to reconcile with the observations that concentrative uptake of prostaglandins is restricted to cortical portions of the nephron (23). Enhancement of renal prostaglandin production after infusion of angiotensin II (72) or bradykinin (55) results in enhancement of urinary excretion of the renal prostaglandins.
However, the PGF-totPGE ratio differs between renal venous plasma (3/l) and urine (l-2/1), perhaps because of greater tubular reabsorption of PGF,, from the urine (55) or greater distal tubular production of PGE2.
In summary, renal prostaglandins are synthesized in medulla and cortex, enter the tubular cells by a facilitated transport process inhibitable by many agents, difRfse into the urine, and are partially reabsorbed by the loop of Henle and the distal tubule. Prostaglandins in the renal arterial blood are filtered and either metab olized or excreted. Renal venous prostaglandins are presumably derived from direct venous drainage of cellular sites of synthesis and also from venous removal of reabsorbed prostaglandins.
Urinary prostaglandins probably reflect renal synthesis.
Prostaglandins and the Renin-Angiotensin System
There is a complex interrelation between renal prostaglandin synthesis and the renin-angiotensin system. McGif'f and his co-workers (142) observed that renal venous PGE-like material increased after intrarenal infusions of angiotensin II. Angiotensin I has similar but less potent effects than angiotensin II (159) . Renal venous PGF,, also increases (55), and urinary excretion of PGE, and PGF,, increase in man (72) and dog (55) after systemic or intrarenal infusions of angiotension II. The extent of the renal vasoconstriction following angiotensin II is modulated by PGE, release, and the vasoactive effects of angiotensin II are potentiated by blockade of prostaglandin synthesis (1, 160). However, angiotensin stimulation of prostaglandin synthesis is not solely mediated by vasoconstriction (43), since angiotension II directly stimulates the production and release of PGE by renal medullary interstitial cells (243, 244) and human vascular endothelial and smooth muscle cells (2, 81) in culture. This effect in vitro is secondary to increased deacylation of phospholipids and, therefore, increased availability of arachidonic acid (244). Angiotensin II has no direct effect on renal medullary microsomal prostaglandin synthetase (55) . There is convincing evidence indicating that renal prostaglandins both increase and decrease renal production of renin. Figure 3 summarizes these concepts. Infusion of arachidonic acid into the renal artery of rats (228) , rabbits (118) , and dogs (31) increases renal venous renin activity. Because indomethacin blocks this response it has been assumed that prostaglandin svnthe- sis precedes renin stimulation (31, 118). Using rabbit renal cortical slices, Weber et al. (229) increased renin release with arachidonic acid and endoperoxides (natural and synthetic). PGF,, diminished r&in synthesis in rabbit cortical slices (229) and cortical cell suspensions (47) . PGE (186, 232) and PGA (82) stimulate renin release in dog and man, respectively, as well as in rabbit renal cortical cell suspensions (PGE only) (47) . Not only does indomethacin block arachidonic acid from stimulating renal renin release (31, 118), but this drug also markedly reduces basal and stimulated renin levels in man (48, 176, 190) and animals (16, 118).
The prostaglandin endoperoxides (PGG2 and PGH,), PGE2, and PGF,, probably act directly on the juxtaglomerular apparatus since they act in vitro on slices and cell suspensions and since their action can be dissociated from the amounts of distal Na delivery to the macula densa (45) (231) and therefore of (228) . The effects of prostacyclin (PGI,) and thromboxane A2 on renin have not been reported. The effects of increased prostaglandin synthesis (171, 234, 235) . Renin suppression after high sodium intake may be secondary, -in part, to a Na-mediated enhancement of the renal furosemide on renin production may be a consequence of prostaglandin 9-ketoreductase (230). Weber and coworkers (230) have reported that high sodium diets in rabbits stimulated the conversion of PGE, to PGF,, by increasing the activity of 9-ketoreductase; the depression of renin may have been secondary to the reduction of the ratio PGEJPGF,, and their effects on the juxtaglomerular cells. Figure 3 illustrates these interactions.
In conclusion we can state that the endoperoxides and PGE, stimulate and PGF,, inhibits renin synthesis and/ or release. The physiological meaning of these effects may depend on a sodium-mediated control of conversion of PGE, to PGF,,. Indomethacin inhibits renal renin secretion under basal as well as stimulated conditions. nous, tissue, or urine prostaglandins after varying sodium intake; 2) blocking prostaglandin synthesis and assessing sodium excretion; 3) evaluating diuretic-induced natriuresis before and after blockade of prostaglandin synthesis. The first approach has not yielded consistent data, possibly because of severe limitations with most of the prostaglandin assays employed in these studies. PGE, and, occasionally PGF or PGA, were measured in renal venous blood (178, 197, 215) , renal tissue (14, 220), urine (230) , and peripheral plasma (246) in man (178, 246) , rabbits (14, 230), dogs (197, 215) , and rats (220) . These authors reported that sodium loading or volume expansion increased renal venous PGE (178, 197, 215) , reduced renal tissue (220) and urinary PGE (230) , and decreased PGA in peripheral plasma (246) and in renal papilla (but not cortex or medulla) (14). The second approach to this question has not yielded any Sodium, Volume, and Diuretics more unanimity.
The clinical literature about the therapeutic use of nonsteroidal anti-inflammatory drugs has Considerable interest has been focused on the follow-frequent references to sodium retention and edema (48 The conscious dogs (3) reduced urine volume and sodium natriuretic action of PGE is probably secondary to renal excretion, especially after sodium loading (3). Chronic vasodilation (34, 138) . Recent studies with the isolated treatment with aspirin and high salt intake increased perfused rabbit nephron (63), renal slices, and nephron plasma and extracellular fluid volumes (209) . Whereas suspensions (55) found no direct effect of PGE, PGF, or conscious dogs increased renal sodium excretion af%er PGA on sodium, chloride, or water transport. However, stokes and Kokko (204) have obtained contrary eviinhibition of prostaglandin synthetase (114), anesthetized dogs showed no effect of indomethacin on basal dence with the perfused cortical collecting tubule from sodium excretion (16). In man there are reports that DOCA-treated rabbits in which they found a direct in-indomethacin (200 mg/day for 4 days) did not alter urine hibitory action of PGE, on sodium reabsorption.
Three major approaches have been used in an experisodium despite reductions of plasma renin activity and aldosterone excretion (176) or that indomethacin (150 mental assessment of the problem of sodium excretion mg/day for 3 days) significantly reduced renal sodium and renal prostaglandin production: 1) measuring ve-excretion on normal or low sodium intake in normal F171 subjects or in patients with renal disease (11, 48). The third approach evaluated the importance of renal prostaglandins as mediators of diuretic-induced natriuresis. Furosemide and ethacrynic acid, administered acutely, increased renal blood flow (187, 188) and this renal &sodilation was blocked by indomethacin (234, 235) . Some authors found no alterations of the diuretic-induced natriuresis in indomethacin-treated animals (16, 234, .235) and man (231) . However, other investigators observed a blunted natriuresis a&er tiosemide (176) or bumetanide (171) in dogs and human subjects pretreated with indomethacin.
IR summary, we feel there is no persuasive evidence that renal prostaglandin production and renal sodium excretion are closely interrelated or interdependent. The existing literature is contradictory and impossible to reconcile. Not only may species differences exist but also anesthetized and acutely operated animals are not comparable to conscious animals and man. Future studies must employ more specific and sensitive assays for PGE, and PGF, and should emphasize urinary excretory levels of these prostaglandins under varying sodium intakes in conscious animals and man.
Renal Blood Flow
Although it is well established that most prostaglandins can alter renal blood flow (RBF), their importance in regulating RBF is uncertain. When PGA1, PGE1 or PGE, are administered to man (100,122) or dogs (10,35, 73), especially intrarenally, RBF increases, with greater changes in the inner cortex than in the outer cortex (35). If the precursor of the renal prostaglandins, arachidonic acid, is infused into the renal artery of dogs (35) or rabbits (118) RBF is enhanced, especially in the inner cortex. It should be noted that nonprostaglandin vasodilators also show preferential inner cortical vasoresponsiveness (203 (51) in the rat. This remains an unresolved but important question because of the work on renal prostaglandin metabolism in hypertensive rat models (see below). PGF, has no effect on renal blood flow in the dog (35, 74) or is slightly vasodilatory (73) . PGD, may be vasodilatory in the kidney since it is vasodepressor in effect after systemic administration (13). The endoperoxides vasoconstrict the canine renal vasculature (79) although they are vasodepressor in e&t after systemic administration in the rat (13). In summary, it is reasonable to conclude that in response to ischemia and vasoconstriction the kidney produces more prostaglandins, especially PGE, and PGF,. PGE, modulates the renal vascular resistance by exerting a vasodilatory effect. If prostaglandin synthesis is inhibited, the influence of vasoconstrictors is accentuated. There is no good evidence that basal or resting RBF is significantly supported by the continued generation of renal prostaglandins.
Prostuglandins and Renal Excretion of Water
The major mechanisms involved in renal water excretion are the action of vasopressin on water transport in the distal nephron, its production and release from the central nervous system, and the maintenance of medullary solute concentration.
Since PGEz is synthesized in the renal medullary interstitial and collecting tubular cells (105, 200) and concentrations of PGE, in these areas of the renal medulla may be high, many workers have sought a role for prostaglandins in the regulation of water excretion. Prostaglandins may influence water excretion by affecting any or all of these mechanisms.
Most investigations have concentrated on the effects of prostaglandins of the E series on water permeability in the distal nephron or toad bladder. PGE, inhibits vasopressin-stimulated water transport and cyclic AMP generation in toad bladder (129) ,, rabbit renal tubule (85), hamster medulla and papilla (139) , and rat inner medullary tissue slices (17 (128) , and in the Brattleboro rat deficient in endogenous vasopressin (227) . It seems likely that prostaglandins of the E series can inhibit water reabsorption in the distal nephron by inhibiting vasopressin stimulation of adenyl cyclase. Prostaglandins may thus effect a negative feedback to vasopressin (see Fig. 4) .
Vasopressin production or release by the central nervous system may be stimulated by prostaglandins.
Intracarotid infusions of PGE, have an antidiuretic effect in rats (226) . An increased level of vasopressin has been found in anesthetized dogs following ventriculocisternal injection of PGE, (238) . It has also been shown that PGE, infused intravenously in dogs has an antidiuretic effect which is abolished by hypophysectomy (22). It has been suggested that the effect of prostaglandins on renal blood flow may alter medullary solute concentrations. There is no evidence that endogenous renal prostaglandins alter medullary hemodynamics enough to reduce solute concentrations and increase renal water excretion by this mechanism alone. Indomethacin enhances the in vivo action of vasopressin in conscious rats without a change in total RBF (21).
Interpretation of the many studies seeking to define the effect of prostaglandins on renal water excretion has been limited by the use of PGE, rather than PGE, in the majority of in vivo and in vitro studies and by the use of indomethacin, which has actions other than prostaglandin synthetase inhibition.
The conflict generated by reports that PGE, enhances the effect of vasopressin may be explained as a dose-dependent phenomenon. At concentrations of 2. 10B6 M, PGE, enhances theophylline-stimulated water flow in the toad bladder, stimulates adenyl cyclase, and fails to inhibit vasopressinstimulated water flow (66) .
The physiological significance of enhanced production or release and peripheral antagonism of vasopressin by endogenous prostaglandins is still to be determined. The major influence of the prostaglandins on renal water excretion would appear to be the inhibition of vasopressin-stimulated water reabsorption (see Fig. 4 ).
Hypertension
The McGiff and Vane (149) , it is unnecessary to postulate a role for the prostaglandins as hormones in the circulation; direct local action on vascular smooth muscle and on renal vascular resistance by prostaglandins gene& ated in these tissues could significantly alter systemic arterial blood pressure. The relationship of prostaglandins to hypertension has been described in three different ways: renal prostaglandin deficiency causes hypertension (121), prostaglandin excess in the kidney causes experimental hypertension in the rat (12, 174), and increased renal production of prostaglandins occurs in response to the hypertension (52) . The problem has been studied by prostaglandin administration in hypertensive animals and man through measurement of renal prostaglandins in tissue or blood, by assessment of prostaglandin synthetase and dehydrogenase levels in kidney, by administration of indomethacin to hypertensive animals and human subjects, and by implantation of renal medullary tissue into hypertensive recipients.
One must be cautious in interpreting the possible effects of any of the prostaglandins on systemic arterial blood pressure because there may be species differences in response to systemic administration (e.g., PGD,) (7, 13, 106), or within the same species different vascular beds may constrict or dilate (e.g., PGG, and PGH,) (13, 79, 135). The acute systemic administration of PGE, (198) caused a greater depression of blood pressure in hypertensive rats of the Okamoto strain than in norm* tensive controls (198) . However, equivalent vasodepressor responses to PGE, were observed in New Zealand hypertensive rats and controls (12). PGG,, PGH,, and PGD, were also vasodepressor in rats, and PGG, and PGH2 caused a greater decrement of blood pressure in the hypertensive rats (New Zealand) than in the norm* tensive controls (13). It is unlikely that these types of studies will unravel, the role of prostaglandins in hypertension.
The reports of measurement of renal venous or tissue prostaglandins in man and animals are replete with the methodologic problems of the assays. Tobian and coworkers (218) (219) (220) and others found decreased granular-ity of the medullary interstitial cells of various hypertensive models (136)) suggesting increased synthesis of renal prostagl .andins. Subsequently, prostaglandins have been measured in peripheral or renal venous plasma, renal tissue, or urine in experimental and human hypertension. Table 1 summarizes these conflicting reports. In our opinion inaccuracy of assays accounts for much of the controversy and uncertainty.
In the fixture clarifi cation should be possi ble if more accurate radioimmunoasays or GC-MS are used to measure PGE,.
Several investigators have measured degradative and synthetic enzymes~ from renal tissue of hypertensive rats. The New Zealand (12) and Japanese SHR (174) had decreased renal activity of 15-hydroxydehydrogenase prior to the onset of hypertension.
Although these authors found no increase of prostaglandin synthesis, we have reported that renal medullary prostaglandin synthetase increases affer the blood pressure rises in Japanese SHR (52, 53) . Whereas Armstrong and co-workers (12) believe that decreased renal catabolism of PGE, may cause hypertension in the rat, we have speculated that renal PGE, synthesis increases as a secondary -response to modulate the elevated pressure (52, 53) .
The potential role of prostaglandin synthesis in the control of blood pressure could possibly be elucidated by studies in normotensive and hypertensive animals and man in which prostaglandin synthesis has been inhibited.
Indomethacin, administered acutely, raises blood pressure in normotensive rabbits (46, 116) ; chronic dosage also increases blood pressure in normal rabbits (38). Indomethacin augments the hypertension in Goldblatt rats (182, 196) , in rabbits (189) , and in SHR (127) . Chronic use of prostaglandin synthetase inhibitors in man may slightly increase the blood pressure (176) and it does enhance the pressor response curve to angiotensin II (160) . These studies are hard to interpret, since indomethacin has other effects besides inhibition of synthetase (see below). Moreover, systemic administration inhibits vascular as well as renal production of prostaglandin, thereby nullifying any specific interpretations. Finally, the innovative experiments of Muirhead et al. (154, 155, 157) should be mentioned.
They have shown that implantation of renal medullary tissue (154, 155, 157) or of renal medullary interstitial cells from culture (157) will reduce the blood pressure of dogs, rats, and rabbits with diverse types of hypertension.
Since indomethacin did not block the vasodepressor effects of these implants and there was no change in sodium balance, Muirhead believes that a nonprostaglandinlipid accounts for the decrement of BP (157) .
In conclusion, there exists abundant evidence that the renal prostaglandins may be involved, either primarily or secondarily, in many types of hypertension. The literature is confusing and conflicting.
Future emphasis should be placed on the accurate measurement of PGE, in urine and renal venous blood.
Renal Failure, Acute and Chronic, Bartter's Syndrome Prostaglandins are the most recent in a series of vasoactive agents tried, without success, to reverse acute renal failure in experimental animals and in man. Although infusion of PGE, increases total renal blood flow (153, 185) and increases urine flow and sodium excretion in some instances of acute renal failure (153), it does not increase GFR. If, in acute renal failure, the decrease in filtration fraction is associated with tierent arteriolar constriction and efferent arteriolar dilatation (65, 184 ) the failure of PGE and other vasodilators to restore the altered hemodynamics could be explained if these substances acted only on the efferent arteriole. Circumstantial evidence has been presented to support the hypothesis that renal prostaglandins protect against the development of a circulatory type of acute renal failure. In rabbits, indomethacin in high doses enhances glycerol-induced acute renal failure but has no effect on (221) . However, indomethacin has no effect on the acute renal failure induced by either glycerol or mercuric chloride in rats (170, 221) . If prostaglandins synthesized in the medulla move to the cortex via the distal tubular fluid, the loss of this pathway in acute renal failure may lead to the unopposed vasoconstrictor action of angiotensin II, which has been suggested as an important mechanism mediating acute renal failure (140, 169) . In a rabbit model of ischemic acute renal failure, renomedullary autotransplants, when implanted prior to the ischemic injury, decreased the death rate of the treated animals by 50% (93). This result compared favorably to the nontreated group, of which all died (93). Neither the factor responsible for this protective effect against ischemic injury nor that responsible for the antihypertensive feet produced by renal medullary implants is known.
efDuring the course of studies evaluating the possible beneficial effects of indomethacin in diverse types of renal glomerular disease, Donker's laboratory (11, 48) has established that indomethacin, 150 mg/day, rapidly and reversibly reduces renal blood flow (10.25%) and glomerular filtration rate (lO-35%). These decrements are potentialed by low intakes of sodium, and similar though less severe changes were also observed in normal subjects on a low sodium diet (48) . Aspirin caused similar reversible alterations of renal blood flow and glomerular filtration rate in patients with systemic lupus erythematosus with nephritis (113) . The decrements of creatinine clearance were correlated with decreases of urinary PGE, and comparable changes of renal function were induced by ibuprofen, naproxen and indomethacin (33, 113) . Depressed renal function has also been observed in premature infants treated with indomethacin to induce closure of patent ductus arteriosus (69,96) and after administration of indomethacin or ibuprofen to patients with cirrhosis and ascites (241) . These studies strongly suggest that renal production of prostaglandins contributes to the maintenance of renal blood flow in patients with acti ve glomerular disease or when the renin-angiotensin system is activated by a low sodium intake or by pathophysiologic processes. Bartter's syndrome, a complex and rare disorder, is characterized by renal losses of potassium and sodium, hypokalemia, hyperreninemia, hyperaldosteronism, juxtaglomerular hyperplasia, resistance to the pressor action of angiotensin II, and normal blood pressure. Multiple reports have documented the beneficial effects of therapy with inhibitors of prostaglandin synthetase (indomethacin, aspirin and ibuprofen) (62, 80, 90, 167, 225) . Increased renal excretion of PGE has been documented in two studies (79, 90) . The report of elevated plasma levels of PGA, (62) is hard to interpret because PGA* has not been found in human plasma analyzed by gas chromatography-mass spectroscopy (70) . Hyperplasia of the renal-medullary interstitial cells has been found in some instances (225) . Is is unknown whether prostaglandin overproduction is a primary or a secondary process in this condition. PGE, and arachidonic acid enhance renal excretion of potassium &r acute administration to normal animals (73 214). Potassium depletion in dogs stimulates renal excretion of PGE and indomethacin reverses some of the metabolic abnormalities (77) . Therapy with inhibitors of prostaglandin synthesis causes partial clinical improvement in patients with Bartter's syndrome concomitant with a positive balance of sodium and potassium, increased plasma potassium, decreased plasma renin and urinary aldosterone, and partial restoration of the sensitivity to the pressor action of infused angiotensin II (62, 80, 90, 166, 225) .
Prostaglandins and Erythropoiesis
Erythropoietin is produced by the kidney in response to hypoxia. However, neither the nature or location of the sensing mechanism nor the factors mediating this response are known. Renal artery constriction to 30% of RBF in dogs causes an increase in renal venous erythropoietin and PGE concentrations.
Both these effects are blocked by indomethacin (87) . Following PGE, and Ez infusions into isolated hypoxic dog kidneys there is an increase in erythropoietin production (86, 179) . PGE, infusions cause an increase in renal cyclic AMP (179) and cyclic AMP influences the renal release of em poietin affer a variety of erythropoietic stimuli (187) . PGE has a direct stimulatory effect on marrow erythropoiesis, (50) and potentiates the action of small amounts of erythropoietin on the incorporation of 5gFe into red cells in marrow culture (50) . It appears, therefore, that prostaglandins influence erythropoietin release from the kidney and also affect erythropoietin action on the bone marrow.
Critique
The major problem which has confronted investigators in prostaglandin research has been assay accuracy and reliability. Table 2 lists most of the assays used in the papers cited in this review. These methods differ substantially in sensitivity, specificity, reproducibility, practicality, and cost. It is not our purpose to provide a detailed assessment of each type of measurement.
Samuelsson et al. (192) have recently reviewed this issue. We believe, however, that a significant portion of the TABLE   3 . Effects of indomethacin* were given to the accuracy of the assays. GC-MS is the standard against which assays must be evaluated, but it Reduce prostaglandin production by inhibition of the cyclois impractical to suggest that this technique be applied oxygenase (PG synthetase) (68) generally. Once verified, radioimmunoassay is the most practical, sensitive, and specific method of measureInhibit prostaglandin degradation bY prostaglandin ment (49, 181) . The technique used in handling of the l!%hydroxydehydrogenase (91) sample prior to assay is of critical importance. Platelets
Inhibit PGE conversion to PGF via 9-ketoreductase (206) rele.ase large quantities of TXB2, PGE2, and PGF, during aggregation and coagul .ation (192) and, consequently, plasma rather than serum must be obtained with a minimum of platelet trauma (49) . Peripheral plasma concentrations of the prostaglandins are not very useful (192) . Renal venous effluent or urine may be more so and are the preferable samples to use. RIA of PGA in plasma or tissue has very limited significance because of the substantial evidence indicating that it is not a significant or usual end product of arachidonic acid metabolism in the kidney (28, 70, 117,212 ). Prostaglandins are not stored within cells (8,36) and measurement of tissue concentrations is less desirable than utilization of venous effluent or urine. Urine has the additional advantages over. plasma of being free of platelets and other cells and of providing a continuous and integrated measure of renal prostaglandin synthesis. It should be stressed that urine prostaglandin excretory rates underestimate true renal turnover because a fraction is secreted directly into the renal venous blood and because a fraction is excreted or secreted as metabolites (55, 83, 192) . Furth ermore, renal tissue concentrations of prostaglandins vary between cortex and medulla and increase very rapidly within minutes &r death (52) .
Many experiments have been conducted with indomethacin and conclusions have been drawn ascribing the results to inhibition of prostaglandin synthesis. The diverse actions of the nonsteroidal inhibitors of prostaglandin synthetase are listed in Table 3 . Some of these actions occur only with high concentrations and may not be pertinent to many of the experimental applications of the drug. Investigators should use different types of inhibitors, such as meclofenamate, aspirin, or Ro 20. 5720, to avoid indomethacin-specific problems. Additionally, it should be demonstrated that the chosen drug, at the dose used, actually does inhibit prostaglandin synthesis under the conditions of the experiment.
The use of anesthetized and laparotomized animals and of ex vivo perfused kidneys has led to an overestimate of the importance of the renal prostaglandins in the regulation-of resting or basal RBF (217) . These preparations are unavoidably traumatized and have increased renal production of prostaglandins, in part secondary to activation of renin and angiotensin.
Future work should stress the use of conscious animals or anesthetized animals with minimal surgical stress (e.g., retroperitoneal flank approach to the kidney).
The Future
The role of prostaglandins in the control of renal Portions of this work were supported by National Institutes of Health Grant HL 20224, and by the Vermont Heart Association.
Inhibit renal tubular transport of prostaglandins in slices (27) and in vivo (183) Inhibit cellular efflux of cyclic AMP in synovial cell cultures (37)
Inhibit cyclic AMP phosphodiesterase (163) Inhibit platelet nicotinate phosphoriboxyl transferase (78) Inhibit uridine-%diphosphoglucose dehydrogenase (123) Compete with aldosterone for renal mineralocorticoid receptors (60) * Some of these effects are shared by other nonsteroidal antiinflammatory drugs; see the individual references for details. The concentrations of indomethacin used in these in vitro experiments may exceed the concentrations achieved in the kidney after in vivo administration.
physiological processes is an important and fruitful area for continued investigation.
We believe that the following are many of the important questions that remain to be answered. What role is played by TXAz, the endoperoxides PGG, and PGHz, prostacyclin (PGI,), and PGD, in the kidney? Do any or all of these substances change RBF and/or interact with the juxtaglomerular cells to alter renin secretion? What are the sites of synthesis of the various prostaglandins within the kidney? Do cells other than renal medullary interstitial cells and collecting tubules produce prostaglandins and does the profile of compounds synthesized differ between cortex and medulla? What are the modes of tubular transport of the prostaglandins and do medullary prostaglandins gain access to the cortex via the lumen or the vasculature? Since virtually all of the stimulants of renal prostaglandin synthesis act by providing more substrate (arachidonic acid), more work must be done on phospholipid deacylation.
How do bradykinin, angiotensin II, and arginine vasopressin interact with phospholipase to deacylate phospholipids? What is the importance of the degradative enzymes 15-hydroxydehydrogense and 9-ketoreductase as control sites for physiological processes tie&d by prostaglandins? What are the physiologically important relationships between aldosterone, sodium status, and kallikrein-kinin and the renal prostaglandins? Does prostaglandin production in the collecting duct exert an important regulatory function on water transport in both normal and diseased kidneys? These are only a few of the questions which must be physiological importance of the renal prostaglandins.
answered before we can understand more completely the REFERENCES 
